Liquidia Q3 loss widens on litigation charge, negating Yutrepia demand
LQDA•Liquidia reported Q3 revenue of $225.30 million and a net loss of $236.33 million, including a $389.7 million litigation settlement charge. Yutrepia patient shipments reached record monthly levels in October.
1. Quarterly results
Liquidia said Q3 revenue surged year over year, driven by higher sales volume of Yutrepia inhalation powder, a larger prescriber base and more first-time prescribers. The company reported a $236.33 million net loss, including a $389.7 million litigation settlement charge, and said Yutrepia patient shipments reached record monthly levels in October.
